Royalty Pharma
RPRX
RPRX
413 hedge funds and large institutions have $8.18B invested in Royalty Pharma in 2024 Q4 according to their latest regulatory filings, with 78 funds opening new positions, 158 increasing their positions, 135 reducing their positions, and 50 closing their positions.
Holders
413
Holders Change
+22
Holders Change %
+5.63%
% of All Funds
5.5%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
78
Increased
158
Reduced
135
Closed
50
Calls
$18.1M
Puts
$3.2M
Net Calls
+$14.9M
Net Calls Change
-$4.48M
Top Buyers
| 1 |
1
Adage Capital Partners
Boston,
Massachusetts
|
$433M |
| 2 |
2
Norges Bank
Oslo,
Norway
|
$124M |
| 3 |
3
BlackRock
New York
|
$649M |
| 4 |
4
Citadel Advisors
Miami,
Florida
|
$73.9M |
| 5 |
5
BNP Paribas Financial Markets
Paris,
France
|
$42M |
